News
03-12-2010, 03:30 AM
Pfizer Inc. announced today that two Phase 3 studies of Sutent® (sunitinib malate) in advanced breast cancer did not meet their primary endpoints. The SUN 1064 Phase 3 study of sunitinib in combination with docetaxel for the first-line treatment of patients with advanced HER-2 negative breast cancer did not show a statistically significant improvement in progression-free survival compared with docetaxel alone.
More... (http://www.news-medical.net/news/20100312/Two-Phase-3-studies-of-Sutent-in-advanced-breast-cancer-fail-to-meet-primary-endpoints.aspx)
More... (http://www.news-medical.net/news/20100312/Two-Phase-3-studies-of-Sutent-in-advanced-breast-cancer-fail-to-meet-primary-endpoints.aspx)